Diabetes & Metabolic Medicines · LP-060
Glipizide Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-060Diabetes & Metabolic Medicines
- Generic identity
- GlipizideTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-060
- Generic identity
- Glipizide
- Presentation
- Tablet
- Catalogue strength
- 5 mg; 10 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Glipizide.
- Dosage form: Tablet.
- Catalogue strength / concentration: 5 mg; 10 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Diabetes & Metabolic Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Release character, tablet technology, score/alteration instructions and dissolution specification.
- Whether the common blister description is a controlled SKU for both strengths.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
Current external labels show glipizide extended-release products at strengths overlapping the catalogue. That demonstrates why LP-060 release character must remain held until controlled Luang documentation is available.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 5 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Do not infer immediate-release or extended-release character from tablet + strength. |
| B | 10 mg | Tablet | — | Catalogue lists blister 10 x 10 tablets; strength-specific controlled SKU evidence not supplied | Do not infer immediate-release or extended-release character from tablet + strength. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Glipizide is a sulfonylurea used in selected type 2 diabetes treatment plans. It increases insulin release and therefore has a clinically important risk of hypoglycaemia. Immediate-release and extended-release versions may have different instructions; a general tablet description does not resolve that distinction. This ingredient profile is educational and does not establish Luang Pharma approved labeling or the suitability of a particular strength for an individual.
Clinical context and therapeutic role
Professional selection includes assessment of glycaemic goals, organ function, meal patterns and the consequences of hypoglycaemia for the individual. A clinician should review other diabetes medicines and any previous severe low-glucose episodes. The treatment plan should identify how response will be monitored and how illness or poor food intake will be handled. Type 1 diabetes and diabetic ketoacidosis require different management; an oral sulfonylurea is not an adequate substitute.
Selected safety context
Hypoglycaemia may cause sweating, tremor, confusion, seizures or loss of consciousness and can require emergency treatment. Missed meals, alcohol, older age, kidney or liver disease and interacting medicines may increase risk. Gastrointestinal symptoms and weight gain can occur. Beta blockers can obscure some warning signs. Pregnancy requires review of the diabetes plan. Confirm the formulation before altering a tablet or switching products, and do not interpret strength alone as evidence of release characteristics.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A diabetes-care professional should confirm the formulation, glycaemic objective, renal function and hypoglycaemia risk. The person should have an individualized monitoring and illness plan; this educational page does not supply dose-selection or conversion instructions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: GlipizideArchived source classification: NLM-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Glipizide extended-release tablets — external label exampleArchived source classification: US official drug label example | Source revision recorded: Updated 8 January 2026; Archived access check: 2026-09-11 | External comparator showing an extended-release glipizide formulation; not evidence that LP-060 is extended-release or equivalent. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-060.
Professional enquiries
Request product-specific evidence for LP-060.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.